Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

97 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Huntsville, Alabama, United States
  • research Site Mesa, Arizona, United States
  • Research Site Phoenix, Arizona, United States
View all 246 locations
View Trial Details
Completed

CLARITY Extension Study

NCT00641537

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Boulder, Colorado, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Northbrook, Illinois, United States
View all 116 locations
View Trial Details
Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

NCT01930708

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Innsbruck, Austria
  • Research Site Klagenfurt, Austria
  • Research Site Linz, Austria
  • Research Site Salzburg, Austria
View all 90 locations
View Trial Details
Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

NCT00203021

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Teva Investigational Site 009 Los Angeles, California, United States
  • Teva Investigational Site 004 Los Angeles, California, United States
  • Teva Investigational Site 008 New Haven, Connecticut, United States
  • Teva Investigational Site 005 Baltimore, Maryland, United States
View Trial Details
Completed

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Brain Diseases, +16 more
Locations
  • Novartis Investigative Site Cullman, Alabama, United States
  • Novartis Investigative Site San Francisco, California, United States
  • Novartis Investigative Site Centennial, Colorado, United States
  • Novartis Investigative Site Miami, Florida, United States
View all 72 locations
View Trial Details
Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Homewood, Alabama, United States
  • Research Site Sun City, Arizona, United States
  • Research Site La Jolla, California, United States
  • Research Site Los Angeles, California, United States
View all 44 locations
View Trial Details
Completed

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

NCT02720107

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Ostfildern, Baden-Wurttemberg, Germany
  • Novartis Investigative Site Altenholz-Stift, Germany
  • Novartis Investigative Site Aschaffenburg, Germany
  • Novartis Investigative Site Berlin, Germany
View all 26 locations
View Trial Details

Related conditions